A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge

Post-marketing reporting of adverse drug events is essential for new medications, as pre-FDA approval studies lack sufficient subject numbers to detect signals for rare events. Prescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have equaled or excee...

Descripción completa

Detalles Bibliográficos
Autores principales: Josyln, James A., Khattak, Furqan H., Geraci, Stephen A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916542/
https://www.ncbi.nlm.nih.gov/pubmed/29707095
http://dx.doi.org/10.14740/jocmr3394w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916542/
https://www.ncbi.nlm.nih.gov/pubmed/29707095
http://dx.doi.org/10.14740/jocmr3394w

Ejemplares similares